Taken together, these results require validation in prospective studies that also include lung adenocarcinomas with metastases to other anatomical sites, further supporting the clinical utility of PINK1 and PI3K immunoexpression for prognostic assessment. This evidence concerns the gene PINK1 and lung adenocarcinoma.